Cytokinetics, Inc. (CYTK)
62.89
-10.29%
Cytokinetics, Inc. (CYTK) is currently trading at $62.89. This represents a loss of 10.29% from the previous session. With a market capitalization of $7.69B, CYTK is a key component of the Health Care sector. Investors looking to trade CYTK should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade CYTK commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Cytokinetics, Inc. (CYTK) shows a bearish trend. Analysts are watching the 69.28 level closely.
Fundamentals
Mkt Cap7.69B
P/E Ratio0.0000
Volume5,038,865
60-Day Technical Chart
Advanced Charting
Need more indicators for CYTK? Use the world's #1 platform.
Open CYTK on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $63
| Metric |
CYTK -10.29% |
BMY -0.50% |
FCX +1.38% |
CTSH +0.00% |
|---|---|---|---|---|
| Price | $62.89 | $61.30 | $68.82 | $61.33 |
| Mkt Cap | $7.69B | $124.84B | $98.91B | $29.33B |
| - | View → | View → | View → |
Latest Headlines
$CYTK stock is down 10% today. Here's what we see in our data.
Quiver Quantitative • Feb 25, 2026
Cytokinetics (CYTK): Analyst Jason Butler Raises Price Target to $96 | CYTK Stock News
GuruFocus • Feb 25, 2026
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside
DirectorsTalk Interviews • Feb 23, 2026
CYTK Sees Positive Analyst Ratings as Needham Raises Price Target | CYTK Stock News
GuruFocus • Feb 25, 2026
New MYQORZO drug wins EU nod to treat symptomatic obstructive HCM
Stock Titan • Feb 17, 2026
● Gemini Agentic AI Analyst Insight for CYTK
Market Education
- The Eagle’s Eye: Spotting Market Opportunities from Above Sep 8, 2025
- I am a newbie Trader, how do I start trading Jul 15, 2023
- Finding Stocks in the Squeeze Zone: Using Finviz Jul 30, 2023
External Research